Selected research
Market Structure
Global Fatty Liver Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Fatty Liver Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The US & Canada market for Fatty Liver Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Fatty Liver Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Fatty Liver Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Fatty Liver Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Fatty Liver Drugs include Allergan, Astra Zenca, Conatus, Gilead Sciences, Hepion Pharmaceuticals, Immuron, Intercept Pharmaceuticals, Madrigal and Merk, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Includes
This report provides an overview of the global Fatty Liver Drugs market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Fatty Liver Drugs and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Fatty Liver Drugs revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Fatty Liver Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.
Fatty Liver Drugs Segment by Company
Allergan
Astra Zenca
Conatus
Gilead Sciences
Hepion Pharmaceuticals
Immuron
Intercept Pharmaceuticals
Madrigal
Merk
Pfizer
Novartis
Takeda
Fatty Liver Drugs Segment by Type
ALD
NAFLD
Fatty Liver Drugs Segment by Application
Hospital
Clinic
Others
Fatty Liver Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Fatty Liver Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Fatty Liver Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Fatty Liver Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Fatty Liver Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Fatty Liver Drugs industry.
Chapter 3: Detailed analysis of Fatty Liver Drugs companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Fatty Liver Drugsrevenue, gross margin, and recent development, etc.
Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 8: Europe by type, by application and by country, revenue for each segment.
Chapter 9: China by type, and by application, revenue for each segment.
Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.
Chapter 12: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- ALD
- NAFLD
Applications
- Hospital
- Clinic
- Others
Companies covered
- Allergan
- Astra Zenca
- Conatus
- Gilead Sciences
- Hepion Pharmaceuticals
- Immuron
- Intercept Pharmaceuticals
- Madrigal
- Merk
- Pfizer
- Novartis
- Takeda
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Market Analysis by Type
- 1.2.1 Global Fatty Liver Drugs Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
- 1.2.2 ALD
- 1.2.3 NAFLD
- 1.3 Market Analysis by Application
- 1.3.1 Global Fatty Liver Drugs Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
- 1.3.2 Hospital
- 1.3.3 Clinic
- 1.3.4 Others
- 1.4 Global Market Growth Prospects
- 1.5 Global Fatty Liver Drugs Growth Trends by Region
- 1.5.1 Global Fatty Liver Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 1.5.2 Fatty Liver Drugs Market Size by Region (2021-2026)
- 1.5.3 Fatty Liver Drugs Market Size by Region (2027-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 1.8 Years Considered
2 Global Fatty Liver Drugs Market Dynamics
- 2.1 Fatty Liver Drugs Industry Trends
- 2.2 Fatty Liver Drugs Industry Drivers
- 2.3 Fatty Liver Drugs Industry Opportunities and Challenges
- 2.4 Fatty Liver Drugs Industry Restraints
3 Competitive Landscape by Company
- 3.1 Global Fatty Liver Drugs Revenue by Company (2021-2026)
- 3.2 Global Fatty Liver Drugs Players Revenue Ranking, 2024 VS 2025 VS 2026
- 3.3 Global Fatty Liver Drugs Key Company Head office and Area Served
- 3.4 Global Fatty Liver Drugs Company, Product Type & Application
- 3.5 Global Fatty Liver Drugs Company Establishment Date
- 3.6 Market Competitive Analysis
- 3.6.1 Global Fatty Liver Drugs Market CR5 and HHI
- 3.6.2 Global Top 5 and 10 Fatty Liver Drugs Players Market Share by Revenue in 2025
- 3.6.3 2025 Fatty Liver Drugs Tier 1, Tier 2, and Tier 3
4 Fatty Liver Drugs Market by Type
- 4.1 Global Fatty Liver Drugs Market Size by Type (2021 VS 2025 VS 2032)
- 4.2 Global Fatty Liver Drugs Market Size by Type (2021-2032)
- 4.3 Global Fatty Liver Drugs Market Size Share by Type (2021-2032)
5 Fatty Liver Drugs Market by Application
- 5.1 Global Fatty Liver Drugs Market Size by Application (2021 VS 2025 VS 2032)
- 5.2 Global Fatty Liver Drugs Market Size by Application (2021-2032)
- 5.3 Global Fatty Liver Drugs Market Size Share by Application (2021-2032)
6 Company Profiles
- 6.1 Allergan
- 6.1.1 Allergan Company Information
- 6.1.2 Allergan Business Overview
- 6.1.3 Allergan Fatty Liver Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.1.4 Allergan Fatty Liver Drugs Product Portfolio
- 6.1.5 Allergan Recent Developments
- 6.2 Astra Zenca
- 6.2.1 Astra Zenca Company Information
- 6.2.2 Astra Zenca Business Overview
- 6.2.3 Astra Zenca Fatty Liver Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.2.4 Astra Zenca Fatty Liver Drugs Product Portfolio
- 6.2.5 Astra Zenca Recent Developments
- 6.3 Conatus
- 6.3.1 Conatus Company Information
- 6.3.2 Conatus Business Overview
- 6.3.3 Conatus Fatty Liver Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.3.4 Conatus Fatty Liver Drugs Product Portfolio
- 6.3.5 Conatus Recent Developments
- 6.4 Gilead Sciences
- 6.4.1 Gilead Sciences Company Information
- 6.4.2 Gilead Sciences Business Overview
- 6.4.3 Gilead Sciences Fatty Liver Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.4.4 Gilead Sciences Fatty Liver Drugs Product Portfolio
- 6.4.5 Gilead Sciences Recent Developments
- 6.5 Hepion Pharmaceuticals
- 6.5.1 Hepion Pharmaceuticals Company Information
- 6.5.2 Hepion Pharmaceuticals Business Overview
- 6.5.3 Hepion Pharmaceuticals Fatty Liver Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.5.4 Hepion Pharmaceuticals Fatty Liver Drugs Product Portfolio
- 6.5.5 Hepion Pharmaceuticals Recent Developments
- 6.6 Immuron
- 6.6.1 Immuron Company Information
- 6.6.2 Immuron Business Overview
- 6.6.3 Immuron Fatty Liver Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.6.4 Immuron Fatty Liver Drugs Product Portfolio
- 6.6.5 Immuron Recent Developments
- 6.7 Intercept Pharmaceuticals
- 6.7.1 Intercept Pharmaceuticals Company Information
- 6.7.2 Intercept Pharmaceuticals Business Overview
- 6.7.3 Intercept Pharmaceuticals Fatty Liver Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.7.4 Intercept Pharmaceuticals Fatty Liver Drugs Product Portfolio
- 6.7.5 Intercept Pharmaceuticals Recent Developments
- 6.8 Madrigal
- 6.8.1 Madrigal Company Information
- 6.8.2 Madrigal Business Overview
- 6.8.3 Madrigal Fatty Liver Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.8.4 Madrigal Fatty Liver Drugs Product Portfolio
- 6.8.5 Madrigal Recent Developments
- 6.9 Merk
- 6.9.1 Merk Company Information
- 6.9.2 Merk Business Overview
- 6.9.3 Merk Fatty Liver Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.9.4 Merk Fatty Liver Drugs Product Portfolio
- 6.9.5 Merk Recent Developments
- 6.10 Pfizer
- 6.10.1 Pfizer Company Information
- 6.10.2 Pfizer Business Overview
- 6.10.3 Pfizer Fatty Liver Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.10.4 Pfizer Fatty Liver Drugs Product Portfolio
- 6.10.5 Pfizer Recent Developments
- 6.11 Novartis
- 6.11.1 Novartis Company Information
- 6.11.2 Novartis Business Overview
- 6.11.3 Novartis Fatty Liver Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.11.4 Novartis Fatty Liver Drugs Product Portfolio
- 6.11.5 Novartis Recent Developments
- 6.12 Takeda
- 6.12.1 Takeda Company Information
- 6.12.2 Takeda Business Overview
- 6.12.3 Takeda Fatty Liver Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.12.4 Takeda Fatty Liver Drugs Product Portfolio
- 6.12.5 Takeda Recent Developments
7 North America
- 7.1 North America Fatty Liver Drugs Market Size (2021-2032)
- 7.2 North America Fatty Liver Drugs Market Size by Type
- 7.2.1 North America Fatty Liver Drugs Market Size by Type (2021-2026)
- 7.2.2 North America Fatty Liver Drugs Market Size by Type (2027-2032)
- 7.2.3 North America Fatty Liver Drugs Market Share by Type (2021-2032)
- 7.3 North America Fatty Liver Drugs Market Size by Application
- 7.3.1 North America Fatty Liver Drugs Market Size by Application (2021-2026)
- 7.3.2 North America Fatty Liver Drugs Market Size by Application (2027-2032)
- 7.3.3 North America Fatty Liver Drugs Market Share by Application (2021-2032)
- 7.4 North America Fatty Liver Drugs Market Size by Country
- 7.4.1 North America Fatty Liver Drugs Market Size by Country (2021 VS 2025 VS 2032)
- 7.4.2 North America Fatty Liver Drugs Market Size by Country (2021-2026)
- 7.4.3 North America Fatty Liver Drugs Market Size by Country (2027-2032)
- 7.4.4 North America Fatty Liver Drugs Market Share by Country (2021-2032)
- 7.4.5 United States
- 7.4.6 Canada
- 7.4.7 Mexico
8 Europe
- 8.1 Europe Fatty Liver Drugs Market Size (2021-2032)
- 8.2 Europe Fatty Liver Drugs Market Size by Type
- 8.2.1 Europe Fatty Liver Drugs Market Size by Type (2021-2026)
- 8.2.2 Europe Fatty Liver Drugs Market Size by Type (2027-2032)
- 8.2.3 Europe Fatty Liver Drugs Market Share by Type (2021-2032)
- 8.3 Europe Fatty Liver Drugs Market Size by Application
- 8.3.1 Europe Fatty Liver Drugs Market Size by Application (2021-2026)
- 8.3.2 Europe Fatty Liver Drugs Market Size by Application (2027-2032)
- 8.3.3 Europe Fatty Liver Drugs Market Share by Application (2021-2032)
- 8.4 Europe Fatty Liver Drugs Market Size by Country
- 8.4.1 Europe Fatty Liver Drugs Market Size by Country (2021 VS 2025 VS 2032)
- 8.4.2 Europe Fatty Liver Drugs Market Size by Country (2021-2026)
- 8.4.3 Europe Fatty Liver Drugs Market Size by Country (2027-2032)
- 8.4.4 Europe Fatty Liver Drugs Market Share by Country (2021-2032)
- 8.4.5 Germany
- 8.4.6 France
- 8.4.7 U.K.
- 8.4.8 Italy
- 8.4.9 Russia
- 8.4.10 Nordic Countries
9 China
- 9.1 China Fatty Liver Drugs Market Size (2021-2032)
- 9.2 China Fatty Liver Drugs Market Size by Type
- 9.2.1 China Fatty Liver Drugs Market Size by Type (2021-2026)
- 9.2.2 China Fatty Liver Drugs Market Size by Type (2027-2032)
- 9.2.3 China Fatty Liver Drugs Market Share by Type (2021-2032)
- 9.3 China Fatty Liver Drugs Market Size by Application
- 9.3.1 China Fatty Liver Drugs Market Size by Application (2021-2026)
- 9.3.2 China Fatty Liver Drugs Market Size by Application (2027-2032)
- 9.3.3 China Fatty Liver Drugs Market Share by Application (2021-2032)
10 Asia (Excluding China)
- 10.1 Asia Fatty Liver Drugs Market Size (2021-2032)
- 10.2 Asia Fatty Liver Drugs Market Size by Type
- 10.2.1 Asia Fatty Liver Drugs Market Size by Type (2021-2026)
- 10.2.2 Asia Fatty Liver Drugs Market Size by Type (2027-2032)
- 10.2.3 Asia Fatty Liver Drugs Market Share by Type (2021-2032)
- 10.3 Asia Fatty Liver Drugs Market Size by Application
- 10.3.1 Asia Fatty Liver Drugs Market Size by Application (2021-2026)
- 10.3.2 Asia Fatty Liver Drugs Market Size by Application (2027-2032)
- 10.3.3 Asia Fatty Liver Drugs Market Share by Application (2021-2032)
- 10.4 Asia Fatty Liver Drugs Market Size by Country
- 10.4.1 Asia Fatty Liver Drugs Market Size by Country (2021 VS 2025 VS 2032)
- 10.4.2 Asia Fatty Liver Drugs Market Size by Country (2021-2026)
- 10.4.3 Asia Fatty Liver Drugs Market Size by Country (2027-2032)
- 10.4.4 Asia Fatty Liver Drugs Market Share by Country (2021-2032)
- 10.4.5 Japan
- 10.4.6 South Korea
- 10.4.7 Taiwan
- 10.4.8 Southeast Asia
- 10.4.9 India
- 10.4.10 Australia
11 South America, Middle East & Africa
- 11.1 South America, Middle East & Africa Fatty Liver Drugs Market Size (2021-2032)
- 11.2 South America, Middle East & Africa Fatty Liver Drugs Market Size by Type
- 11.2.1 South America, Middle East & Africa Fatty Liver Drugs Market Size by Type (2021-2026)
- 11.2.2 South America, Middle East & Africa Fatty Liver Drugs Market Size by Type (2027-2032)
- 11.2.3 South America, Middle East & Africa Fatty Liver Drugs Market Share by Type (2021-2032)
- 11.3 South America, Middle East & Africa Fatty Liver Drugs Market Size by Application
- 11.3.1 South America, Middle East & Africa Fatty Liver Drugs Market Size by Application (2021-2026)
- 11.3.2 South America, Middle East & Africa Fatty Liver Drugs Market Size by Application (2027-2032)
- 11.3.3 South America, Middle East & Africa Fatty Liver Drugs Market Share by Application (2021-2032)
- 11.4 South America, Middle East & Africa Fatty Liver Drugs Market Size by Country
- 11.4.1 South America, Middle East & Africa Fatty Liver Drugs Market Size by Country (2021 VS 2025 VS 2032)
- 11.4.2 South America, Middle East & Africa Fatty Liver Drugs Market Size by Country (2021-2026)
- 11.4.3 South America, Middle East & Africa Fatty Liver Drugs Market Size by Country (2027-2032)
- 11.4.4 South America, Middle East & Africa Fatty Liver Drugs Market Share by Country (2021-2032)
- 11.4.5 Brazil
- 11.4.6 South Africa
- 11.4.7 Saudi Arabia
- 11.4.8 Turkey
- 11.4.9 Argentina
- 11.4.9 UAE
- 11.4.9 Egypt
- 11.4.9 Chile
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
- 13.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst